Bryan T. J. Hennessy
Molecular Biology · 2005–2016
A researcher in the Science corpus: 11 papers; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 97 citations into it
Whom Bryan T. J. Hennessy trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Bryan T. J. Hennessy overall
Papers from Bryan T. J. Hennessy's perspective
Ordered by how strongly the researchers Bryan T. J. Hennessy trusts endorse each paper. Same corpus, a different order for every researcher.
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (Proceedings of the National Academy of Sciences of the United States of America)
- TSC2 mediates cellular energy response to control cell growth and survival. (Cell)
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancer (Nature Reviews. Cancer)
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers (Science)
- TOR, a central controller of cell growth. (Cell)
- The PIK3CA gene is mutated with high frequency in human breast cancers (Cancer Biology & Therapy)
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
- Repeated observation of breast tumor subtypes in independent gene expression data sets (Proceedings of the National Academy of Sciences of the United States of America)
- mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (Cancer Research)
- DAVID: Database for Annotation, Visualization, and Integrated Discovery (Genome Biology)
Their papers
- Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells (2006) — 688 citations
- The energy sensing LKB1–AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis (2007) — 893 citations
- Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery (2005) — 2,176 citations
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer (2012) — 728 citations
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016) — 852 citations
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer (2008) — 1,067 citations
- Network inference using steady-state data and Goldbeter-Koshland kinetics (2012) — 19 citations
- The biology of ovarian cancer: new opportunities for translation (2009) — 1,413 citations
- Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. (2009) — 863 citations
- Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. (2008) — 2,849 citations
- Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. (2007) — 1,500 citations